November 01, 1997; 49 (5) Articles
Sumatriptan nasal spray for the acute treatment of migraine
Results of two clinical studies
R. Ryan, A. Elkind, C. C. Baker, W. Mullican, S. DeBussey, M. Asgharnejad
First published November 1, 1997, DOI: https://doi.org/10.1212/WNL.49.5.1225
R. Ryan
MD
A. Elkind
MD
C. C. Baker
MD
W. Mullican
MD
S. DeBussey
BS
Sumatriptan nasal spray for the acute treatment of migraine
Results of two clinical studies
R. Ryan, A. Elkind, C. C. Baker, W. Mullican, S. DeBussey, M. Asgharnejad
Neurology Nov 1997, 49 (5) 1225-1230; DOI: 10.1212/WNL.49.5.1225
Citation Manager Formats
Make Comment
See Comments

Article Information
vol. 49 no. 5 1225-1230
PubMed:
Print ISSN:
Online ISSN:
History:
- First Published November 1, 1997.
Copyright & Usage:
© 1997
Author Disclosures
- R. Ryan, MD,
- A. Elkind, MD,
- C. C. Baker, MD,
- W. Mullican, MD,
- S. DeBussey, BS and
- M. Asgharnejad, PharmD
- R. Ryan, MD,
- A. Elkind, MD,
- C. C. Baker, MD,
- W. Mullican, MD,
- S. DeBussey, BS and
- M. Asgharnejad, PharmD
- From the Ryan Headache Center (Dr. Ryan), St. Louis, MO; Elkind Headache Center (Dr. Elkind), Mt. Vernon, NY; Headache Institute of Minnesota (Dr. Baker); Minneapolis, MN; MediSphere Medical Research Center (Dr. Mullican), Evansville, IN; and Glaxo Wellcome, Inc. (S. DeBussey and Dr. Asgharnejad), Research Triangle Park, NC.
- Address correspondence and reprint requests to Dr. Robert Ryan, 621 South New Ballas Road, Suite 537, St. Louis, MO 63141.
Article usage
Letters: Rapid online correspondence
No comments have been published for this article.
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Advertisement
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
ARTICLES
A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraineJ. Touchon, L. Bertin, A. J. Pilgrim et al.Neurology, August 01, 1996 -
Brief Communications
Intranasal sumatriptan for the acute treatment of migraine in childrenMichael A. Ueberall, Dieter Wenzel et al.Neurology, April 01, 1999 -
Special Article
Practice guideline update summary: Acute treatment of migraine in children and adolescentsReport of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache SocietyMaryam Oskoui, Tamara Pringsheim, Yolanda Holler-Managan et al.Neurology, August 14, 2019 -
Articles
Naratriptan is effective and well tolerated in the acute treatment of migraineResults of a double-blind, placebo-controlled, crossover studyNinan T. Mathew, Mahnaz Asgharnejad, Margaret Peykamian et al.Neurology, December 01, 1997